Tumor News and Research

RSS

Seno completes PIONEER Pivotal Study of non-invasive Imagio breast imaging system

Seno Medical Instruments, Inc., the company pioneering the development of opto-acoustic technology as a new tool to improve the process of diagnosing breast cancer, announced today it has completed the final phase of the company's U.S.-based PIONEER Pivotal Study of the Imagio® breast imaging system.

1 Oct 2015

Multicenter study shows Monteris’ NeuroBlate System improves outcome in brain tumor patients

Monteris Medical today announced recent data demonstrating that newly diagnosed brain tumor patients undergoing procedures with the NeuroBlate System, a minimally invasive robotic laser thermotherapy tool, experienced improved outcomes.

1 Oct 2015

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer-related deaths among men in the U.S. The challenge with prostate cancer is that the standard treatment methods in the advanced stage of the disease lose effectiveness after about one to two years, leading to recurrence and, ultimately, death. A University of Houston researcher and his team are working to change that.

30 Sep 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

Leading cancer researchers address eight 'big questions'

Leading cancer researchers address eight of the "big questions" facing the field as part of the inaugural issue of Trends in Cancer, published by Cell Press.

30 Sep 2015

Researchers develop a technique that uses platelet membranes to coat anticancer drugs

Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient's own platelets, allowing the drugs to last longer in the body and attack both primary cancer tumors and the circulating tumor cells that can cause a cancer to metastasize. The work was tested successfully in an animal model.

30 Sep 2015

Intratumoral morphological diversity of breast cancer not related to chromosome aberrations

Intratumor morphological heterogeneity (diversity) of breast cancer is not related to chromosome aberrations. This conclusion was made based on the study of one case with aggressive variant of breast cancer - invasive micropapillary carcinoma by researchers from Tomsk State University, Tomsk Cancer Research Institute, and Institute of Medical Genetics.

30 Sep 2015

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, further data to support the efficacy of VARGATEF® (nintedanib*) in combination with docetaxel for the treatment of advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology

29 Sep 2015

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.

29 Sep 2015

Tailorx trial data supports use of Oncotype DX test in patients with early stage breast cancer

Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early stage breast cancer sponsored by the National Cancer Institute, part of the National Institutes of Health, and led by the ECOG-ACRIN Cancer Research Group with support from Genomic Health, Inc.

29 Sep 2015

Unique molecule can bind HIV-infected cells to killer T cells

A unique molecule developed at Duke Medicine, the University of North Carolina at Chapel Hill and MacroGenics, Inc., is able to bind HIV-infected cells to the immune system's killer T cells. It could become a key part of a shock-and-kill strategy being developed in the hope of one day clearing HIV infection.

29 Sep 2015

Scientists develop new molecular toolkit to investigate protein assemblies in human disease

A photograph may reveal how something looks, but direct observation can divulge how the objects behave. The difference can mean life or death, especially when it comes to fighting human disease.

29 Sep 2015

New drug works better than current treatments for advanced kidney cancer

A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.

29 Sep 2015

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors. KTN0158 is a proprietary, humanized anti-KIT IgG1 monoclonal antibody drug candidate being developed as a potential therapy for cancer and mast cell-related diseases.

28 Sep 2015

Multigene test performed on tumor can identify breast cancer patients who can safely avoid chemotherapy

A major study published in the New England Journal of Medicine is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.

28 Sep 2015

Arteries may be best source for detecting circulating tumor cells

As the field of liquid biopsies for tracking disease progression and therapeutic response heats up, many doctors are looking for ways to apply this approach to their patients.

26 Sep 2015

Common IBD therapeutic target may protect against intestinal inflammation

Investigators at Children's Hospital Los Angeles have found that a common therapeutic target for the treatment of inflammatory bowel disease (IBD) may actually protect against intestinal inflammation by inhibiting pathogenic T-cells. This discovery, reported in the October 2015 issue of Gastroenterology, could lead to new treatment options for the 65 percent of individuals with IBD who do not respond or become resistant to anti-TNF medications.

26 Sep 2015

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited.

26 Sep 2015

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

CUMC's Laboratory of Personalized Genomic Medicine granted approval for Columbia Combined Cancer Panel

The Laboratory of Personalized Genomic Medicine at Columbia University Medical Center has been granted full approval by the New York State Department of Health for the Columbia Combined Cancer Panel, (CCCP). This panel queries 467 cancer-related genes and was designed in collaboration with Columbia University Medical Center oncologists.

25 Sep 2015

Tumor News and Research

Seno completes PIONEER Pivotal Study of non-invasive Imagio breast imaging system

Multicenter study shows Monteris’ NeuroBlate System improves outcome in brain tumor patients

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Leading cancer researchers address eight 'big questions'

Researchers develop a technique that uses platelet membranes to coat anticancer drugs

Intratumoral morphological diversity of breast cancer not related to chromosome aberrations

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Tailorx trial data supports use of Oncotype DX test in patients with early stage breast cancer

Unique molecule can bind HIV-infected cells to killer T cells

Scientists develop new molecular toolkit to investigate protein assemblies in human disease

New drug works better than current treatments for advanced kidney cancer

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Multigene test performed on tumor can identify breast cancer patients who can safely avoid chemotherapy

Arteries may be best source for detecting circulating tumor cells

Common IBD therapeutic target may protect against intestinal inflammation

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

CUMC's Laboratory of Personalized Genomic Medicine granted approval for Columbia Combined Cancer Panel

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Exploring the G:Box and for high-quality imaging

Latest News